SOHM Inc. (OTC:SOHM) Stock In Focus After Latest News

There are a number of companies that would come on the radar of investors this morning on the back of the developments from yesterday, and one of those could be the pharmaceutical and biotech company SOHM Inc. (OTC:SOHM). The company, involved in the marketing and manufacturing of generic drugs for a range of treatments, was in focus on Monday after it announced the preliminary data related to its ABBIE Genome Editing Technology. The company announced that the technology had been successful in engineering a T-cell from a healthy human donor and in killing cancer cells in an experimental cancer model as well.

SOHM noted in its news release that the company presented the data at the 2024 AACR conference that took place in San Diego. In this context, it should be noted that the path-breaking method for immunotherapy to tackle cancer involves a virus-based delivery system. However, the ABBIE system could be delivered to the patient as purified protein or mRNA with guide RNA and polynucleic acid without using viruses. The system had been successful in killing the CAR-T cells with great efficiency, the company noted.

The Chief Operating Officer of SOHM, David Aguilar, noted yesterday that the preliminary data was interesting and implied that ABBIE could be a useful tool that could help in the development of immunotherapies. He went on to note that CAR T-cell therapy was a path-breaking type of cancer treatment that deployed the power of the patient’s native immune system for the purpose of targeting and destroying the cancer cells. In the news release, SOHM noted that the reason behind the importance of CAR T-cell therapy was that it had the capability of providing personalized and targeted treatment for patients with specific types of cancer. It remains to be seen if the stock gets any action today.

Ian Leigh

Ian Leigh is a specialist in analyzing stocks, SEC and OTC filings, and financials of public and privately-held companies. He has played a significant role in M&A activity, consulting with publicly-held firms on acquisitions and divestitures. He also consults on valuations and branding. He lectures at major universities and teaches at specialty financial schools.